Searchable abstracts of presentations at key conferences in endocrinology

ea0016oc4.9 | Bone and adrenal | ECE2008

Teriparatide (TPTD) treatment followed by either zoledronic acid (ZOL) 5 mg once yearly or strontium ranelate (SR) 2 g daily: preliminary results from the ZOSTER-Study

Riedmuller Gunter , Fahrleitner Astrid , Dobnig Harald , Piswanger Claudia , Stiegler Claudia , Stepan Vinzenz , Obermayer-Pietsch Barbara , Hans-Peter Dimai

Background: TPTD treatment has been shown to reduce vertebral and non-vertebral fracture risk in postmenopausal osteoporosis efficiently. However, gains in bone mass achieved by this treatment are almost lost 2 years after cessation of treatment, unless consecutively followed by an antiresorptive treatment such as alendronate.Subjects and methods: In the present prospective randomised open-labelled study in 52 pmp women, we investigated the effect of eit...